Quick summary
Quick summary: Archived - Increased risk of marked hepatic enzyme elevations in patients taking SOMAVERT (pegvisomant) in combination with a somatostatin analogue - For the Public .
Public recall detail
Archived - Increased risk of marked hepatic enzyme elevations in patients taking SOMAVERT (pegvisomant) in combination with a somatostatin analogue - For the Public
Recall
Safety notice
Recommended action
Recommended action: compare your product with the official notice and follow the instructions published by the official source.
Recall details
Quick summary: Archived - Increased risk of marked hepatic enzyme elevations in patients taking SOMAVERT (pegvisomant) in combination with a somatostatin analogue - For the Public .
Official details
Affected product details
Structured information extracted from the official Health Canada recall notice.
Affected products
Issue
What you should do
Additional official information
FAQ
Frequently asked questions
Answers based on the official recall notice.
Product images
Official product images from Health Canada.
Starting...
Explore more
Related recalls
Similar recalls and safety notices.